Geode Capital Management, LLC Eagle Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 105,846 shares of EGRX stock, worth $68,799. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,846

Previous 108,004 2.0%

Holding current value

$68,799

Previous $604,000 35.1%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.71 - $6.07 $8,006 - $13,099	-2,158 Reduced 2.0%	105,846 $392,000
Q2 2024 Aug 09, 2024	SELL	$3.34 - $5.6 $412,947 - $692,367	-123,637 Reduced 53.37%	108,004 $604,000
Q1 2024 May 13, 2024	BUY	$4.26 - $6.51 $27,033 - $41,312	6,346 Added 2.82%	231,641 $1.21 Million
Q4 2023 Feb 13, 2024	BUY	$4.63 - $15.21 $25,238 - $82,909	5,451 Added 2.48%	225,295 $1.18 Million
Q3 2023 Nov 13, 2023	BUY	$15.21 - $22.88 $73,768 - $110,968	4,850 Added 2.26%	219,844 $3.47 Million
Q2 2023 Aug 11, 2023	BUY	$17.74 - $31.87 $210,059 - $377,372	11,841 Added 5.83%	214,994 $4.18 Million
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $71,370 - $97,088	2,848 Added 1.42%	203,153 $5.76 Million
Q4 2022 Feb 13, 2023	BUY	$24.98 - $39.77 $92,625 - $147,467	3,708 Added 1.89%	200,305 $5.85 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $178,308 - $318,012	6,749 Added 3.55%	196,597 $5.19 Million
Q2 2022 Aug 12, 2022	SELL	$41.26 - $51.35 $630,205 - $784,319	-15,274 Reduced 7.45%	189,848 $8.43 Million
Q1 2022 May 13, 2022	BUY	$44.58 - $52.6 $32,097 - $37,872	720 Added 0.35%	205,122 $10.2 Million
Q4 2021 Feb 11, 2022	SELL	$45.82 - $56.9 $377,877 - $469,254	-8,247 Reduced 3.88%	204,402 $10.4 Million
Q3 2021 Nov 12, 2021	BUY	$43.79 - $55.78 $490,053 - $624,233	11,191 Added 5.56%	212,649 $11.9 Million
Q2 2021 Aug 13, 2021	BUY	$36.86 - $44.5 $564,363 - $681,339	15,311 Added 8.23%	201,458 $8.62 Million
Q1 2021 May 12, 2021	BUY	$40.32 - $50.97 $1.18 Million - $1.49 Million	29,198 Added 18.6%	186,147 $7.77 Million
Q4 2020 Feb 12, 2021	SELL	$41.72 - $51.34 $122,323 - $150,528	-2,932 Reduced 1.83%	156,949 $7.31 Million
Q3 2020 Nov 13, 2020	SELL	$37.02 - $51.28 $227,895 - $315,679	-6,156 Reduced 3.71%	159,881 $6.79 Million
Q2 2020 Aug 13, 2020	BUY	$43.24 - $55.02 $500,200 - $636,471	11,568 Added 7.49%	166,037 $7.97 Million
Q1 2020 May 14, 2020	SELL	$34.37 - $60.07 $228,491 - $399,345	-6,648 Reduced 4.13%	154,469 $7.11 Million
Q4 2019 Feb 13, 2020	BUY	$54.32 - $64.31 $115,538 - $136,787	2,127 Added 1.34%	161,117 $9.68 Million
Q3 2019 Nov 12, 2019	BUY	$53.25 - $59.98 $117,256 - $132,075	2,202 Added 1.4%	158,990 $8.99 Million
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $255,376 - $320,247	5,479 Added 3.62%	156,788 $8.73 Million
Q1 2019 May 14, 2019	BUY	$38.66 - $51.82 $744,823 - $998,364	19,266 Added 14.59%	151,309 $7.64 Million
Q4 2018 Feb 13, 2019	BUY	$36.72 - $67.73 $468,106 - $863,422	12,748 Added 10.69%	132,043 $5.32 Million
Q3 2018 Nov 13, 2018	BUY	$66.65 - $83.86 $1.15 Million - $1.45 Million	17,260 Added 16.92%	119,295 $8.27 Million
Q2 2018 Aug 14, 2018	BUY	$51.25 - $76.62 $1.16 Million - $1.73 Million	22,621 Added 28.48%	102,035 $7.72 Million
Q1 2018 May 15, 2018	BUY	$52.16 - $66.86 $93,575 - $119,946	1,794 Added 2.31%	79,414 $4.18 Million
Q4 2017 Feb 13, 2018	SELL	$49.6 - $60.87 $787,449 - $966,372	-15,876 Reduced 16.98%	77,620 $4.15 Million
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $174,405 - $225,806	3,741 Added 4.17%	93,496 $5.58 Million
Q2 2017 Aug 14, 2017	BUY	N/A	89,755	89,755 $7.08 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $8.46M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Eagle Pharmaceuticals, Inc. Transaction History